Ocuphire Pharma Investor Presentation Deck
APX3330 Key Takeaways
DR is one of the largest markets in retina with 10M patients in US and over 100M worldwide
Majority of the NPDR patients are not candidates for approved biologics treatments and are left untreated
► APX3330 first-in-class oral drug that inhibits Ref-1 which reduces VEGF and inflammatory cytokines to normal
physiological levels
Prevention of worsening is a clinically meaningful potential registration endpoint that was met in ZETA-1 study
▸ No subjects (0%) treated with APX3330 had a binocular ≥ 3-step DRSS worsening from baseline compared with
16% for placebo (p=0.04) after 24 weeks of treatment
► APX3330 demonstrated favorable safety & tolerability in diabetic patients
> An EOP2 meeting with FDA is confirmed in Q4 2023
APX3330 has the potential to be an early, non-invasive preventative treatment for the 8 million NPDR patients with the
potential to treat other organs affected by diabetes (e.g., kidney disease, peripheral neuropathy)
Broad prescriber base including general ophthalmology, optometry and primary care due to favorable safety
Ocuphire
PHARMA
30View entire presentation